var data={"title":"Lanthanum carbonate: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Lanthanum carbonate: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6437?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=lanthanum-carbonate-patient-drug-information\" class=\"drug drug_patient\">see &quot;Lanthanum carbonate: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186951\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Fosrenol</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5594603\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Fosrenol</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186966\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Phosphate Binder</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186953\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Reduction of serum phosphorous:</b> Oral: Initial: 1,500 mg daily divided and taken with or immediately after meals; typical increases of 750 mg daily every 2 to 3 weeks are suggested as needed to reduce the serum phosphate level &lt;6 mg/dL (1.92 mmol/L); usual dosage range: 1,500 to 3,000 mg daily; doses of up to 4,500 mg have been evaluated</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186954\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16160264\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16160265\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186934\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Packet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Fosrenol: 750 mg (10 ea, 90 ea); 1000 mg (10 ea, 90 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Chewable, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Fosrenol: 500 mg, 750 mg, 1000 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg, 750 mg, 1000 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186923\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13247742\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM271798.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/+Btau8Jzc5BLV85NUiGV68sD5lwAt1zs6wDgW7tUS9eA==&amp;TOPIC_ID=10219\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM271798.pdf</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186936\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer with or immediately after meals.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chewable tablet: Tablet should be chewed completely prior to swallowing; do not swallow whole. Tablet may be crushed to aid in chewing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral powder: Sprinkle powder on a small quantity of applesauce or other similar food (not liquid) and administer immediately. Do not store for future use. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186935\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Reduction of serum phosphorous:</b> Reduction of serum phosphate in patients with end-stage renal disease (ESRD)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7914236\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Lanthanum may be confused with lithium</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186927\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (oral powder: &le;18%; chewable tablets: &le;7%), nausea (oral powder: &le;18%; chewable tablet: &le;11%), vomiting (oral powder: &le;18%; chewable tablets: &le;9%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypocalcemia (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal pain (chewable tablet: 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Accidental injury (tooth injury with chewable tablets), allergic skin reaction, constipation, dyspepsia, fecal impaction, gastrointestinal perforation, hypophosphatemia, intestinal obstruction (including ileus and subileus), intestinal perforation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186939\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bowel obstruction, fecal impaction, ileus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in U.S. labeling): Hypersensitivity to lanthanum carbonate or any component of the formulation; hypophosphatemia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186925\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal obstruction: Serious gastrointestinal (GI) obstruction, ileus, subileus, GI perforation, and fecal impaction have been reported, some requiring surgery or hospitalization. Risk factors include patients with altered GI anatomy (eg, diverticular disease, peritonitis, history of GI surgery, GI cancer, GI ulceration), hypomotility disorders (eg, constipation, ileus, subileus, diabetic gastroparesis), or concomitant medications (eg, calcium channel blockers); may also occur in patients without history of GI disease.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Biliary obstruction: Use with caution in patients with biliary obstruction (elimination of lanthanum may be reduced in these patients).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal disease: Use with caution in patients with active peptic ulcer, ulcerative colitis, or  Crohn disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment (elimination of lanthanum may be reduced in these patients).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tablet: Chew thoroughly to decrease risk of serious adverse GI effects; do not swallow whole.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Abdominal x-rays: May have a radiopaque appearance in patients taking lanthanum.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone deposition: Rising lanthanum levels were observed in bone biopsies of patients treated for up to 4.5 years. Lanthanum deposits into developing bone, including growth plates; consequences on developing bone are not known. Use in children is not recommended.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299576\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186928\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10219&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Ampicillin: Lanthanum may decrease the serum concentration of Ampicillin.  Management: Administer oral ampicillin at least two hours before or after lanthanum.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin-Converting Enzyme Inhibitors: Lanthanum may decrease the serum concentration of Angiotensin-Converting Enzyme Inhibitors.  Management: Administer angiotensin-converting enzyme inhibitors at least two hours before or after lanthanum.<b> Exceptions: </b>Enalaprilat.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antacids: May diminish the therapeutic effect of Lanthanum.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bacampicillin: Lanthanum may decrease the serum concentration of Bacampicillin.  Management: Administer bacampicillin at least 2 hours before or after lanthanum.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloroquine: Lanthanum may decrease the serum concentration of Chloroquine.  Management: Administer chloroquine at least two hours before or after lanthanum.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Halofantrine: Lanthanum may decrease the serum concentration of Halofantrine.  Management: Administer halofantrine at least two hours before or after lanthanum.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HMG-CoA Reductase Inhibitors (Statins): May decrease the serum concentration of Lanthanum. Management: Administer HMG-CoA reductase inhibitors at least two hours before or after lanthanum.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinolones: Lanthanum may decrease the serum concentration of Quinolones.  Management: Administer oral quinolone antibiotics at least one hour before or four hours after lanthanum.<b> Exceptions: </b>Gemifloxacin; LevoFLOXacin (Oral Inhalation); Lomefloxacin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracyclines: Lanthanum may decrease the serum concentration of Tetracyclines.  Management: Administer oral tetracycline antibiotics at least two hours before or after lanthanum.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thyroid Products: Lanthanum may decrease the serum concentration of Thyroid Products.  Management: Administer oral thyroid products at least two hours before or after lanthanum.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186930\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186942\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse effects have been observed in some animal reproduction studies. The effect on absorption of vitamins and nutrients has not been studied. Lanthanum is not recommended for use during pregnancy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20547661\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;\">It is not known if lanthanum is excreted in breast milk. Consider the possibility of infant exposure when administering to a breast-feeding woman.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2886994\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Take  with or immediately after meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186932\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Serum calcium and phosphorus: Frequency of measurement may be dependent upon the presence and magnitude of abnormalities, the rate of progression of CKD, and the use of treatments for CKD-mineral and bone disorders (KDIGO 2009): CKD stage 5 and 5D: Every 1-3 months</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2886993\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Corrected total serum calcium (K/DOQI 2003): CKD stage 5: 8.4-9.5 mg/dL (2.1-2.37 mmol/L); KDIGO guidelines recommend maintaining normal ranges for CKD stage 5 and 5D (KDIGO 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Phosphorus (K/DOQI 2003): CKD stage 5 (including those treated with dialysis): 3.5-5.5 mg/dL (1.13-1.78 mmol/L); KDIGO guidelines recommend maintaining normal ranges for CKD stage 5 and lowering elevated phosphorus levels toward the normal range for CKD stage 5D (KDIGO 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Serum calcium-phosphorus product (K/DOQI 2003): CKD stage 5: &lt;55 mg<sup>2</sup>/dL<sup>2</sup></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186924\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Disassociates in the upper gastrointestinal tract to lanthanum ions (La<sup>3+</sup>) which bind to dietary phosphate resulting in insoluble lanthanum phosphate complexes and a net decrease in serum phosphate and calcium levels.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186938\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: &lt;0.002%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: &gt;99% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Not metabolized </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Plasma: 53 hours; Bone: 2-3.6 years </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Feces primarily; urine &lt;2%</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F186941\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Chewable</b> (Fosrenol Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (45): $648.37</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">750 mg (15): $216.12</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 mg (10): $144.08</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Chewable</b> (Lanthanum Carbonate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (45): $583.52</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">750 mg (15): $194.51</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 mg (10): $129.67</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Pack</b> (Fosrenol Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">750 mg (10): $144.08</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 mg (10): $144.08</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5539886\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Fosbait (LK);</li>\n      <li>Fosrenol (AT, AU, BB, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HK, HN, ID, IL, IS, JP, KR, LB, LT, LU, LV, MT, NL, NO, PH, PL, PT, RO, SE, SG, SI, SK, TH, TR, TW);</li>\n      <li>Foznol (IE, IT);</li>\n      <li>Lanthonate (IN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Behets GJ, Verberckmoes SC, D'Haese PC, et al, &ldquo;Lanthanum Carbonate: A New Phosphate Binder,&rdquo; <i>Curr Opin Nephrol Hypertens</i>, 2004, 13:403-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lanthanum-carbonate-drug-information/abstract-text/15199290/pubmed\" target=\"_blank\" id=\"15199290\">15199290</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fosrenol (lanthanum) [prescribing information]. Lexington, MA: Shire US Inc; February 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fosrenol (lanthanum) [product monograph]. Saint-Laurent, Quebec, Canada: Shire Pharma Canada ULC; March 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Guideline 13: Treatment of Bone Disease in Chronic Kidney Disease.&rdquo;  Available at  https://www.kidney.org/sites/default/files/docs/boneguidelines.pdf</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group, &quot;KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD),&quot; <i>Kidney Int Suppl</i>, 2009, 76(S113):1-130.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lanthanum-carbonate-drug-information/abstract-text/19644521/pubmed\" target=\"_blank\" id=\"19644521\">19644521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group, &quot;KDIGO 2012 Clinical Practice Guidelines for the Evaluation and Management of Chronic Kidney Disease,&quot;<i>Kidney Inter, Suppl</i>, 2013, 3:1-150.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10219 Version 108.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F186951\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F5594603\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F186966\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F186953\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F186954\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F16160264\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F16160265\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F186934\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F186923\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F13247742\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F186936\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F186935\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F7914236\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F186927\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F186939\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F186925\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299576\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F186928\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F186930\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F186942\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20547661\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F2886994\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F186932\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F2886993\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F186924\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F186938\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F186941\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F5539886\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10219|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=lanthanum-carbonate-patient-drug-information\" class=\"drug drug_patient\">Lanthanum carbonate: Patient drug information</a></li></ul></div></div>","javascript":null}